Published in Proc Natl Acad Sci U S A on April 01, 1987
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A (1988) 3.53
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A (1995) 1.56
Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother (1989) 1.40
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother (1995) 1.36
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother (1992) 1.25
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1987) 1.10
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1994) 1.09
Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry. Antimicrob Agents Chemother (1995) 1.05
Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. J Clin Invest (1987) 1.05
Inhibition of immune functions by antiviral drugs. J Clin Invest (1991) 1.04
Use of recombinant retroviruses to characterize the activity of antiretroviral compounds. J Virol (1991) 1.04
Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 1.03
Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages. Antimicrob Agents Chemother (1993) 0.95
Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1997) 0.92
Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. Antimicrob Agents Chemother (1995) 0.90
Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol (2012) 0.89
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci U S A (1994) 0.89
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob Agents Chemother (1994) 0.86
Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol (2007) 0.85
Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrob Agents Chemother (1989) 0.84
In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother (1990) 0.83
Differential inhibition of 2'-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2',3'-dideoxycytidine by dipyridamole. Antimicrob Agents Chemother (1991) 0.83
Identification and some properties of a unique DNA polymerase from cells infected with human B-lymphotropic virus. J Virol (1989) 0.82
3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation. Proc Natl Acad Sci U S A (1992) 0.81
Vaccine and antiviral strategies against infections caused by human immunodeficiency virus. CMAJ (1988) 0.80
Regulation of the reverse transcriptase of human immunodeficiency virus type 1 by dNTPs. Proc Natl Acad Sci U S A (1992) 0.79
Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine. Antimicrob Agents Chemother (1996) 0.77
Pathogenesis of human immunodeficiency virus infection and prospects for control. Yale J Biol Med (1988) 0.75
Kinetic approaches to understanding the mechanisms of fidelity of the herpes simplex virus type 1 DNA polymerase. J Nucleic Acids (2010) 0.75
Clinical significance and characterization of AZT-resistant strains of HIV-1. Can J Infect Dis (1991) 0.75
2'3'-Dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow. J Clin Invest (1995) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (1986) 6.53
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Human T-lymphotropic retroviruses. Nature (1985) 5.04
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature (1984) 4.35
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). Science (1984) 1.74
Homology of human T-cell leukaemia virus envelope gene with class I HLA gene. Nature (1983) 1.58
Effects of 2',3'-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol (1984) 1.57
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1986) 1.56
Polymer synthesis in killed bacteria: lethality of 2',3'-dideoxyadenosine. J Bacteriol (1966) 1.26
Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc Natl Acad Sci U S A (1974) 1.26
The enzymatic termination of polydeoxynucleotides by 2',3'-dideoxyadenosine triphosphate. Proc Natl Acad Sci U S A (1969) 1.09
Nucleosides. XI. 2',3'-dideoxycytidine. J Org Chem (1967) 0.95
Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells. J Exp Med (1986) 0.93
Differential methylation of class I histocompatibility antigen genes in T-cell lines derived from two different types of T-cell malignancies. Leuk Res (1984) 0.82
The sequence of the human genome. Science (2001) 101.55
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (1986) 6.53
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 5.46
Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science (1984) 5.43
A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science (1982) 5.30
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature (1987) 4.35
Molecular targets for AIDS therapy. Science (1990) 4.28
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. N Engl J Med (1975) 3.81
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan. Proc Natl Acad Sci U S A (1982) 3.75
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med (1997) 3.44
A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med (1984) 3.41
Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15. AIDS Res Hum Retroviruses (1987) 3.03
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 3.01
Strategies for antiviral therapy in AIDS. Nature (1987) 2.95
Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med (1985) 2.95
Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol (1990) 2.93
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
The virus of Japanese adult T-cell leukaemia is a member of the human T-cell leukaemia virus group. Nature (1982) 2.75
Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J Virol (1981) 2.72
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science (1984) 2.70
A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A (1997) 2.63
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A (1989) 2.62
Primary structure analysis of the major internal protein p24 of human type C T-cell leukemia virus. Proc Natl Acad Sci U S A (1982) 2.57
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Envelope sequences of two new United States HIV-1 isolates. Virology (1988) 2.44
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Isolation and tissue distribution of type-C virus and viral components from a gibbon ape (Hylobates lar) with lymphocytic leukemia. Virology (1978) 2.37
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer (1997) 2.30
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Epidemiology of human T-cell leukemia/lymphoma virus. J Infect Dis (1983) 2.26
Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources. Proc Natl Acad Sci U S A (1985) 2.26
Reverse transcriptase activity of human acute leukaemic cells: purification of the enzyme, response to AMV 70S RNA, and characterization of the DNA product. Nat New Biol (1972) 2.25
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
Fraud in breast-cancer trials. N Engl J Med (1994) 2.16
Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly. AIDS Res Hum Retroviruses (1990) 2.15
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
Expression of alternatively spliced human T-lymphotropic virus type I pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell leukemia/lymphoma and healthy carriers. Proc Natl Acad Sci U S A (1992) 2.05
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem (1994) 2.03
Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res (2001) 2.02
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. J Natl Cancer Inst Monogr (1998) 2.01